新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 韩国CRO SillaJen 1亿5千万收购Jennerex

韩国CRO SillaJen 1亿5千万收购Jennerex

来源:生物谷 2013-12-02 21:43

2013年12月2日讯 /生物谷BIOON/ --就在Jennerex公司与其合作伙伴宣布他们的溶瘤疫苗Pexa-Vec针对肝癌的二期研究失败几个月后,韩国的合作研究机构SillaJen公司宣布将花费1亿5千万收购Jennerex公司并继续该项目的研发。这一消息并未透露太多细节,但是这一收购案给Pexa-Vec项目以卷土重来的机会。今年9月份,Jennerex公司宣布Pexa-Vec项目的二期研究失败,但是并未透露具体的研究数据,仅表示他们坚信这一疫苗在癌症治疗上的有效性并继续论证三期研究的可能性。现在,SillaJen公司的CEO在一份声明中表示,他认为Pexa-Vec在多种癌症中都有明显的效果。Pexa-Vec主要是通过病毒转录、抑制肿瘤处血管生长以及激发机体免疫反应三方面来治疗肿瘤。

近年来世界各大医药公司纷纷投入重资研发肿瘤疫苗,但是成果却并不乐观。但是有研究显示这种治疗方法有希望与其他抗癌疗法联合起来更好地治疗癌症。(生物谷Bioon.com)

详细英文报道:

A few months after Jennerex and its partner Transgene reported that their oncolytic cancer vaccine Pexa-Vec flunked a Phase IIb endpoint on overall survival in liver cancer, the private South Korean CRO SillaJen has stepped in to buy the company in a deal worth $150 million at the high end.

The release includes no mention of an upfront payment or what kind of payout Jennerex's investors will get in the near term, if any. But the new owner is described as a longtime investor in Jennerex committed to late-stage studies of Pexa-Vec.

There also aren't many details available over the extent of their recent trial failure. A short statement in early September was released without any data on outcomes. Both partners, though, stoutly insisted that they were nearing a decision on a Phase III study while other mid-stage trials were pursued in other areas. And the new owners insisted they are staying on track for a Phase III study without so much as a nod at the recent setback.

"The clinical data with Jennerex's lead asset, Pexa-Vec (JX-594), is compelling in multiple tumor types," says SillaJen CEO Eun-Sang Moon in a statement. "In a randomized Phase II trial, as published in Nature Medicine in February 2013, Pexa-Vec demonstrated an overall survival advantage as first-line therapy for patients with advanced hepatocellular carcinoma ("HCC", or primary liver cancer). Given the high unmet medical need in this patient population, these initial results are highly encouraging and warrant confirmation in a Phase III trial. We have also seen promising activity in colorectal and kidney cancers, the latter of which included two patients with complete tumor responses."

The lead therapy is designed to mount a three-pronged attack on cancer: combating cancer cells through viral replication, cutting the blood supply to tumors and spurring an immune response to fight the cancer. Back in 2009 Jennerex reported signs of efficacy and safety in a dose-escalating Phase I trial.

Cancer vaccines, which have inspired significant investments in search of offering a new approach in the fight against cancer, have had a poor record in late-stage studies. But a wide variety of clinical studies are still being mounted in hopes of finding an approach that will work -- probably in combination with other therapies.

France's Transgene, which owns 8.5% of Jennerex, says it is looking forward to partnering with SillaJen.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库